Abstract
Introduction: All biological treatments improve lung function and symptoms in clinical trials, however the fastness of action has not been properly studied.
Aims: To compare the early improvement of asthma control test (ACT) and forced expiratory volume in 1s (FEV1) after three different biological treatments in severe asthma patients.
Methods: Retrospective observational study. Patients treated between 2018-2021 with omalizumab, benralizumab and mepolizumab at least for 3 months, were included. Demographic variables, administered drug and treatment effectiveness (ACT:baseline-1-3 months and FEV1:baseline-3 months) were collected.
Results: Seventy patients (41(58.6%) females) with 53.0±15.2 years. Thirty-six (51.4%) received omalizumab, 19(27.2%) benralizumab and 15 (21.4%) mepolizumab. ACT improvement was significative (p<0.05) at 3 months respect baseline in all groups. Patients with omalizumab (p=0.01) and benralizumab (p<0.0001) showed a significative clinical improvement at 1 month. FEV1 improvement was significative in omalizumab (p=0.02) and benralizumab (p=0.003) groups after 3 months treatment.
Conclusions: Biological treatments studied improved asthma control after 3 months. Moreover, omalizumab and benralizumab showed an early improvement in ACT at first month. All treatments had a similar effect in FEV1, but highlight, patients with benralizumab had a lower value at baseline.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 3918.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
